10-QPeriod: Q2 FY2018

BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2018

Filed August 9, 2018For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed its 10-Q for the period ending August 9, 2018, presenting a standard quarterly update. Investors should note that the filing largely outlines the expected structure of a 10-Q, detailing financial statements, management's discussion and analysis, and various other disclosures. A thorough review of the specific financial performance and operational updates within the detailed sections (Items 1 and 2 of Part I) is crucial for a comprehensive understanding of the company's current standing and outlook. The report indicates that the company is adhering to standard SEC reporting requirements, which includes disclosing financial positions, operational results, and risk factors. Investors will need to carefully examine the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section for insights into revenue, expenses, profitability, and any significant changes impacting the company's financial health. Furthermore, the "Risk Factors" section (Item 1A of Part II) will provide critical information about potential challenges and uncertainties the company faces.

Financial Highlights

52 data points
Beta

Revenue

$52.80M

88.2% Gross Margin

Net Income

-$157.72M

-298.7% Net Margin

EPS (Diluted)

$-0.22

Total Assets

$1.65B

Cash & Equivalents

$438.42M

Free Cash Flow

-$127.75M

Financial Statements
Beta
Revenue$52.80M
Cost of Revenue$6.26M
Gross Profit$46.55M
R&D Expenses$164.25M
SG&A Expenses$45.16M
Operating Expenses$215.85M
Operating Income-$163.05M
Interest Expense$421K
Net Income-$157.72M
EPS (Basic)$-0.22
Shares Outstanding (Basic)698.51M

Key Highlights

  • 1The 10-Q filing covers the quarterly period ending August 9, 2018, providing a routine update on BeOne Medicines Ltd.'s financial and operational status.
  • 2Part I of the filing includes the company's interim financial statements and the critical Management's Discussion and Analysis (MD&A) section.
  • 3Item 2 of Part I, the MD&A, is essential for understanding the company's financial condition, results of operations, and any significant trends or uncertainties.
  • 4Part II addresses Other Information, including a key section on Legal Proceedings and Risk Factors that investors should scrutinize.
  • 5The 'Risk Factors' section (Item 1A) outlines potential challenges and uncertainties that could impact the company's future performance.
  • 6The filing structure suggests adherence to standard SEC reporting, but specific financial and operational details will be contained within the detailed sections.

Frequently Asked Questions

This 10-Q filing provides BeOne Medicines Ltd. with its quarterly report to the Securities and Exchange Commission (SEC). It offers investors an update on the company's financial performance, financial condition, and other relevant business activities for the period ending August 9, 2018.

The most critical information for investors will be found in Part I, Item 1 (Financial Statements) for the raw financial data, and particularly Item 2 (Management's Discussion and Analysis of Financial Condition and Results of Operations) for management's insights and explanations regarding the company's performance and outlook.

The specific risks facing BeOne Medicines Ltd. are detailed in Part II, Item 1A (Risk Factors). Investors should carefully read this section to understand potential challenges, uncertainties, and factors that could negatively impact the company's business, financial condition, or results of operations.

Part II, Item 1 (Legal Proceedings) of the 10-Q filing would contain information regarding any material legal proceedings to which BeOne Medicines Ltd. is a party. Investors should refer to this section for updates on such matters.